Bendamustine [BEN1]

The first line treatment of low grade lymphoma where all the following criteria are met:

1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
2. Low grade non-Hodgkin’s lymphoma
3. Option for 1st-line chemotherapy only
4. To be used within the treating Trust’s governance framework, as Bendamustine is not licensed in this indication Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.

NHS funded From: 08 July 2018

Additional information

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: n/a - NHS clinical (NA)

Current Form Version

Note

The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• BEN1_prior_to_cdf_1.361
• OBIBEN1_prior_to_cdf_1.361